Filtered By:
Source: Heart Rhythm
Condition: Atrial Fibrillation
This page shows you your search results in order of relevance. This is page number 16.
Order by Relevance | Date
Total 356 results found since Jan 2013.
Left Atrial Appendage Closure Device Implantation in Patients with Prior Intracranial Hemorrhage
The Watchman ™ device (Boston Scientific, MN), used for left atrial appendage closure (LAAC) was approved for stroke prevention in patients with atrial fibrillation (AF) and an appropriate rationale to avoid long-term oral anticoagulation. Patients with AF and prior intracranial hemorrhage (ICH) were excluded from clinical trials due to perceived risks of peri-operative anticoagulation.
Source: Heart Rhythm - December 2, 2018 Category: Cardiology Authors: Erika Hutt, Oussama M. Wazni, Walid I. Saliba, Mohamed Kanj, Khaldoun G. Tarakji, Jose Aguilera, Amr F. Barakat, Peter Rasmussen, Ken Uchino, Andrew Russman, Shazam Hussain, Dolora Wisco, Samir Kapadia, Bruce D. Lindsay, Ayman A. Hussein Source Type: research
Atrial Fibrillation Occurring During Head-up Tilt Test: Once detected, AF should be monitored, regardless of how it is detected
Atrial fibrillation (AF) often progresses to more sustained forms and raises the risk of ischemic stroke or sinus node dysfunction (SND). However, there has been no data on the clinical outcomes of AF developed during head-up tilt testing (HUT).
Source: Heart Rhythm - December 4, 2018 Category: Cardiology Authors: Jun Hyung Kim, Sung Ho Lee, Seung-Jung Park, Kyoung Min Park, Young Keun On, June Soo Kim Source Type: research
CHA2DS2-VASc scores and Intermountain Mortality Risk Scores for the joint risk stratification of dementia among patients with atrial fibrillation
High CHA2DS2-VASc scores in atrial fibrillation (AF) patients are generally associated with increased risks of stroke and dementia. At lower CHA2DS2-VASc scores, there remains an unquantifiable cranial injury risk, necessitating an improved risk assessment method within these lower-risk groups.
Source: Heart Rhythm - January 1, 2019 Category: Cardiology Authors: Kevin G. Graves, Heidi T. May, Victoria Jacobs, Kirk U. Knowlton, Joseph B. Muhlestein, Donald L. Lappe, Jeffrey L. Anderson, Benjamin D. Horne, T. Jared Bunch Tags: Featured Article Source Type: research
Left Atrial Appendage Closure Device Implantation in Patients with Atrial Fibrillation and Prior Intracranial Hemorrhage “No Man Left Behind”
Several LAA closure devices have been developed for patients with atrial fibrillation (AF) seeking an alternative to long-term oral anticoagulation (OAC). The PROTECT AF trial was the first multicenter randomized controlled trial (RCT) comparing LAA closure device vs. OAC with Warfarin. Primary safety events were statistically more frequent in the device group (7.4% vs. 4.4%). At a mean follow up of 3.8 years LAA closure device showed superiority for the primary efficacy endpoint (i.e., composite of stroke, cardiovascular death and systemic embolism), with a 34% relative risk reduction in total mortality1-3 However, with t...
Source: Heart Rhythm - January 14, 2019 Category: Cardiology Authors: Luigi Di Biase, Jorge Romero Source Type: research
Atrial fibrillation occurring during head-up tilt testing: Once detected, atrial fibrillation should be monitored, regardless of how it is detected
Atrial fibrillation (AF) often progresses to more sustained forms and increases the risk of ischemic stroke or sinus node dysfunction. However, there have been no data on the clinical outcomes of patients who developed AF during head-up tilt testing (HUT).
Source: Heart Rhythm - December 4, 2018 Category: Cardiology Authors: Jun Hyung Kim, Sung Ho Lee, Seung-Jung Park, Kyoung Min Park, Young Keun On, June Soo Kim Source Type: research
Cryoballoon Pulmonary Vein Ablation and Left Atrial Appendage Closure Combined Procedure: a long term follow up analysis Cryoablation with Concomitant Left Atrial Appendage Closure
combined left atrial appendage closure (LAAC) and cryo-energy pulmonary vein isolation (PVI) procedure has been proven safe and effective in managing stroke in patients with non-valvular atrial fibrillation (AF), although most data refer to procedures performed using radiofrequency (RF) as main energy source.
Source: Heart Rhythm - March 26, 2019 Category: Cardiology Authors: Gaetano Fassini, Alessio Gasperetti, Gianpiero Italiano, Stefania Riva, Massimo Moltrasio, Antonio Dello Russo, Michela Casella, Anna Maltagliati, Fabrizio Tundo, Benedetta Majocchi, Luca Arioli, Ghaliah Al-Mohani, Gianluca Pontone, Mauro Pepi, Claudio To Source Type: research
Atrial fibrillation patients with hypertrophic cardiomyopathy: Do we need new stroke risk stratification?
Due to very high thromboembolic risk, life-long oral anticoagulation is recommended in all hypertrophic cardiomyopathy (HCM) patients with non-valvular atrial fibrillation (NVAF).1-3 We read with great interest the paper by Tsuda et al.4 who rightly emphasized the importance of HCM on thromboembolism in patients with AF.
Source: Heart Rhythm - April 3, 2019 Category: Cardiology Authors: Boyoung Joung, Gregory Y.H. Lip Source Type: research
Cryoballoon pulmonary vein ablation and left atrial appendage closure combined procedure: A long-term follow-up analysis
The combined left atrial appendage closure (LAAC) and cryoenergy pulmonary vein isolation (PVI) procedure has been proven safe and effective in managing stroke in patients with nonvalvular atrial fibrillation (AF), although most data refer to procedures performed using radiofrequency as the main energy source.
Source: Heart Rhythm - March 26, 2019 Category: Cardiology Authors: Gaetano Fassini, Alessio Gasperetti, Gianpiero Italiano, Stefania Riva, Massimo Moltrasio, Antonio Dello Russo, Michela Casella, Anna Maltagliati, Fabrizio Tundo, Benedetta Majocchi, Luca Arioli, Ghaliah Al-Mohani, Gianluca Pontone, Mauro Pepi, Claudio To Source Type: research
To the Editor — Patients with atrial fibrillation with hypertrophic cardiomyopathy: Do we need new stroke risk stratification?
Because of high thromboembolic risk, lifelong oral anticoagulation is recommended in all patients with nonvalvular atrial fibrillation (NVAF) with hypertrophic cardiomyopathy (HCM).1 –3 We read with great interest the article by Tsuda et al,4 who rightly emphasized the importance of HCM in thromboembolism in patients with AF.
Source: Heart Rhythm - April 3, 2019 Category: Cardiology Authors: Boyoung Joung, Gregory Y.H. Lip Tags: Letter to the Editor Source Type: research
EP News: Clinical
Packer et al (JAMA March 15, 2019;https://doi.org/10.1001/jama.2019.0693; Epub ahead of print, PMID 30874766) evaluated whether catheter ablation is more effective than conventional medical therapy for improving outcomes in atrial fibrillation (AF). A total of 2204 symptomatic patients with AF 65 years and older or younger than 65 years with 1 or more risk factors for stroke were enrolled. The catheter ablation group (n = 1108) underwent pulmonary vein isolation. The drug therapy group (n = 1096) received standard rhythm and/or rate control drugs.
Source: Heart Rhythm - May 24, 2019 Category: Cardiology Authors: N.A. Mark Estes Tags: EP News Source Type: research
Thromboembolic, Bleeding, and Mortality Risks among Patients with Nonvalvular Atrial Fibrillation Treated with Dual Antiplatelet Therapy versus Oral Anticoagulants: A Population-Based Study
Dual antiplatelet therapy (DAPT) with aspirin plus clopidogrel is used for stroke prevention in patients with atrial fibrillation (AF) when patients refuse to use oral anticoagulants (OAC) in clinical practice. However, there are limited clinical data comparing these treatments.
Source: Heart Rhythm - July 31, 2019 Category: Cardiology Authors: Wallis C.Y. Lau, Ian J. Douglas, Ian C.K. Wong, Liam Smeeth, Gregory Y.H. Lip, Wai K. Leung, Chung-Wah Siu, Bernard M.Y. Cheung, Michael T.C. Mok, Esther W. Chan Source Type: research
EP News: Allied Professionals
Di Biase et al (J Am Coll Cardiol 2019;74:1019, PMID 31439209) sought to assess the incidence of thromboembolic (TE) events such as stroke and transient ischemic attack (TIA) in patients with atrial fibrillation (AF) undergoing ablation for AF that included left atrial appendage (LAA) isolation (LAAI). The st udy group comprised all patients who underwent LAAI as part of their ablation strategy and who were without AF 6 months after ablation. All patients were continued on oral anticoagulation (OAC) with either warfarin or direct oral anticoagulant (DOAC) for the first 6 months.
Source: Heart Rhythm - September 15, 2019 Category: Cardiology Authors: Erica S. Zado Tags: EP News Source Type: research
Incidence and Causes of In-hospital Outcomes and 30-day Readmissions After Percutaneous Left Atrial Appendage Closure: A United States Nationwide Retrospective Cohort Study Using Claims Data
Percutaneous left atrial appendage closure (p-LAAC) emerged as an option for stroke prevention in atrial fibrillation (AF) patients ’ ineligible for long-term anticoagulation.Real-world data on its in-hospital and 30-day readmission measures are limited.
Source: Heart Rhythm - September 16, 2019 Category: Cardiology Authors: Venkat L.K. Vuddanda, Mohit K. Turagam, Nikita A. Umale, Zubair Shah, Dhanunjaya R. Lakkireddy, Krzysztof Bartus, Finnian R. McCausland, Poonam Velagapudi, Moussa Mansour, E. Kevin Heist Source Type: research
EP News: Clinical
Yasada et al (N Engl J Med 2019;381:1103, PMID 31475793) conducted a prospective randomized multicenter trial of 2236 patients with atrial fibrillation (AF) who had undergone percutaneous coronary intervention or coronary artery bypass grafting more than 1 year earlier or who had angiographically confirmed coronary artery disease not requiring revascularization. Patients were randomized to monotherapy with rivaroxaban or combination therapy with rivaroxaban plus a single antiplatelet agent. The primary efficacy end point was a composite of stroke, systemic embolism, myocardial infarction, unstable ang ina requiring revas...
Source: Heart Rhythm - October 27, 2019 Category: Cardiology Authors: N.A. Mark Estes Tags: EP News Source Type: research
